Evidence map›Paper›PMID 27698251›Full record

ArticleJournal of clinical pathology2016

Critical evaluation of KCNJ3 gene product detection in human breast cancer: mRNA in situ hybridisation is superior to immunohistochemistry.

Sarah Kammerer, Stephan Wenzel Jahn, Elke Winter, Sylvia Eidenhammer, Simin Rezania, Peter Regitnig, Martin Pichler, Wolfgang Schreibmayer, Thomas Bauernhofer

Open access · hybridAbstract read
In one paragraph

Article in Journal of clinical pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sarah KammererMolecular Physiology Group, Institute of Biophysics, Medical University of Graz, Graz, Austria.
Stephan Wenzel JahnInstitute of Pathology, Medical University of Graz, Graz, Austria.
Elke WinterInstitute of Pathology, Medical University of Graz, Graz, Austria.
Sylvia EidenhammerInstitute of Pathology, Medical University of Graz, Graz, Austria.
Simin RezaniaMolecular Physiology Group, Institute of Biophysics, Medical University of Graz, Graz, Austria.
Peter RegitnigInstitute of Pathology, Medical University of Graz, Graz, Austria.
Martin PichlerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Wolfgang SchreibmayerMolecular Physiology Group, Institute of Biophysics, Medical University of Graz, Graz, Austria.
Thomas BauernhoferResearch Unit on Ion Channels and Cancer Biology, Medical University of Graz, Graz, Austria.
Medical University of Graz · AT

Funding

Austrian Science Fund FWF KLI 182
6 · The paper itself

Abstract

Increased expression levels of KCNJ3 have been correlated with lymph node metastases and poor prognosis in patients with breast cancer, suggesting a prognostic role of KCNJ3 We aimed to establish protocols for the detection of KCNJ3 in formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue. Several antibodies were tested for sensitivity and specificity by western blot, followed by optimisation of the immunohistochemistry (IHC) procedure and establishment of KCNJ3 mRNA in situ hybridisation (ISH). Methods were validated by processing 15 FFPE breast cancer samples for which microarray data were available. Spearman's rank correlation analysis resulted in borderline significant correlation for IHC versus ISH (r

Indexed as

AdultAgedBiomarkers, TumorBlotting, WesternBreastBreast NeoplasmsCarcinomaFemaleG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHEK293 CellsHumansImmunohistochemistryIn Situ HybridizationMCF-7 CellsMiddle AgedParaffin EmbeddingBiomarkers, TumorG Protein-Coupled Inwardly-Rectifying Potassium ChannelsKCNJ3 protein, humanRNA, MessengerANTIBODIESBREAST CANCERIMMUNOHISTOCHEMISTRYIN SITU HYBRIDISATIONMETHODOLOGY

Identifiers

PMID27698251
PMCPMC5256407
OpenAlexW2527723141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.